Synthetic Biologics Names Raymond Stapleton Senior VP Manufacturing

Synthetic Biologics Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, has appointed Raymond Stapleton as senior vice president, manufacturing. Dr. Stapleton will lead the manufacturing team as the company begins to prepare for late-stage clinical trials for its irritable bowel syndrome with constipation (IBS-C) and C. difficile programs, and continues to move its monoclonal antibody (mAb) program forward to address Pertussis (whooping cough).

Dr. Stapleton is a pharmaceutical and biotechnology executive with over 15 years of experience at Merck & Co. Inc., in manufacturing, operations, quality, science, technology, engineering and process development. He most recently served as executive director, global vaccine technology and engineering. During his tenure at Merck, Dr. Stapleton contributed to the scale up, tech transfer and manufacturing product launch of multiple billion dollar franchises including Isentress (oral solid dosage for AIDs), Gardasil (HPV vaccine), Keytruda (anti-PD-1 cancer mAb therapy), and performed process development for the cholesterol lowering therapy Mevacor (lovastatin).